Reed Earns Top-5 Finish at the Monster Mile
DOVER, Del. (June 3, 2017) – Ryan Reed earned a career-best Dover finish with a fifth-place result Saturday afternoon at Dover International Speedway. Reed had a fast No. 16 Lilly Diabetes Ford Mustang and was able to capitalize on pit strategy for track position. Reed led the field to the final stage and over the final 50 laps settled into fifth.
“It was just a solid weekend,” said Reed following the race. “I didn’t feel like we had a winning car but I felt like with Dover being one of my worst race tracks…here and Bristol… I have to get better the most. I spent a lot of time in the Ford simulator and appreciate them for helping me out. We made a great call late on strategy and thought that we had a good enough car to hold on to a top five. It was a nice, cleanly executed afternoon.”
Reed qualified his Lilly Diabetes Ford 17th for Saturday afternoon’s 200-lap race at Dover International Speedway. The first stage was cautioned filled, which was not what Reed and his team needed to see. The No. 16 Lilly Diabetes Ford struggled on restarts and needed the long runs. Despite the multiple cautions and searching for grip, Reed finished up stage one 10th.
Reed lined up ninth for the start of stage two following a pit stop for four tires, fuel, wedge and track bar adjustments. The adjustments helped his forward drive and when the caution came out eight laps shy of the stage two ending, crew chief Phil Gould was able to deploy a strategy call.
Gould called Reed down pit road for four tires, fuel and a wedge adjustment. Reed restarted 20th, but worked his way up to 13th at the end of stage two. The field pitted following the stage, setting Reed up as the leader for the final stage.
Reed led the field to the green for the final stage of the race. With track position and some clear air Reed was able to capitalize and hold his ground in the top five for all of stage three. Reed ultimately crossed the finish line fifth, his best finish at the 1.0-mile “Monster Mile.”
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a wide range of therapies and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com or follow us on Twitter: @LillyDiabetes.